Rapport Therapeutics shares surge over 50% in Tuesday pre-market trading following successful Phase 2 trial
RAPP Rapport Therapeutics Inc
$28.60 +3.74%
View chart & analysis → - 1Rapport Therapeutics' investigational therapy RAP-219 met both primary and secondary endpoints in a Phase 2 clinical trial for patients with bipolar I disorder.
- 2The average reduction in YMRS total score for patients treated with RAP-219 was 15.4 points, compared to 12.3 points for the placebo group.
- 3Rapport Therapeutics plans to meet with the U.S. Food and Drug Administration (FDA) in the first half of 2027 to review clinical results and discuss future registrational study designs.
So what's the key point?
A treatment from Rapport Therapeutics performed well in a clinical trial. Following this news, the stock price rose by more than 50% before the market opened.
Source InvestorsHub +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.